Начало › Рак на белия дроб › Мериленд › Baltimore
Клинични проучвания за Рак на белия дроб в Baltimore, MD
40 проучвания за Рак на белия дроб търсят участници в обекти в и около Baltimore (в радиус от около 30 мили). Отворете проучването, за да видите кой може да участва и как да се свържете с екипа.
Официален текст на проучването (английски)
Търсите участници за проучване? Представяме го в началото на тази страница — $99 за 30 дни →
Chemotherapy Combined With Immunotherapy Versus Immunotherapy Alone for Older Adults With Stage IIIB-IV Lung Cancer, The ACHIEVE Trial
Набиране на участнициФаза 3
- University of Maryland/Greenebaum Cancer Center, Baltimore
- Sinai Hospital of Baltimore, Baltimore
Testing the Addition of a Type of Drug Called Immunotherapy to the Usual Chemotherapy Treatment for Non-small Cell Lung Cancer, an ALCHEMIST Treatment Trial (Chemo-IO [ACCIO])
Набиране на участнициФаза 3
- Greater Baltimore Medical Center, Baltimore
- Sinai Hospital of Baltimore, Baltimore
- MedStar Franklin Square Medical Center/Weinberg Cancer Institute, Baltimore
- и още 4
Substudy 01I: A Study of Investigational Agents in Participants With Previously Treated Stage IV Squamous Non-small Cell Lung Cancer (NSCLC) (MK-3475-01I/KEYMAKER-U01I)
Набиране на участнициФаза 2
- MedStar Franklin Square Medical Center ( Site 0033), Baltimore
Collecting Blood Samples From Patients With and Without Cancer to Evaluate Tests for Early Cancer Detection
Набиране на участнициНаблюдателно проучванеЗдравите доброволци са добре дошли
- Mercy Medical Center, Baltimore
- Sinai Hospital of Baltimore, Baltimore
- MedStar Franklin Square Medical Center/Weinberg Cancer Institute, Baltimore
- и още 2
A Study of HER3-DXd in Subjects With Locally Advanced or Metastatic Solid Tumors
Набиране на участнициФаза 2
- Johns Hopkins University, Baltimore
DK222 Study at Hopkins
Набиране на участнициФаза 1
- Johns Hopkins Hospital, Baltimore
Study of Daraxonrasib (RMC-6236) in Patients With RAS Mutated NSCLC (RASolve 301)
Набиране на участнициФаза 3
- Johns Hopkins University of Medicine, Baltimore
Symbiotic-Lung-01 : A Study to Learn About the Study Medicine Called PF-08634404 in Combination With Chemotherapy in Adult Participants With Locally Advanced or Metastatic Non-Small Cell Lung Cancer
Набиране на участнициФаза 3
- Maryland Oncology Hematology, P.A., Annapolis · на 22 мили
A Study to Investigate Ubamatamab With and Without Marlotamig (REGN7075) in Adult Participants With Advanced/Metastatic Non-Small Cell Lung Cancer (NSCLC)
Набиране на участнициФаза 2
- University of Maryland Greenebaum Comprehensive Cancer Center, Baltimore
Neoadjuvant and Adjuvant Treatment in Resectable Non-small Cell Lung Cancer
Набиране на участнициФаза 2
- Research Site, Baltimore
Testing the Combination of an Anti-cancer Drug, Iadademstat, With Other Anti-cancer Drugs (Atezolizumab or Durvalumab) at Improving Outcomes for Small Cell Lung Cancer
Набиране на участнициФаза 1/2
- University of Maryland/Greenebaum Cancer Center, Baltimore
- Johns Hopkins University/Sidney Kimmel Cancer Center, Baltimore
Study of RMC-5127 in Patients With Advanced KRAS G12V-Mutant Solid Tumors
Набиране на участнициФаза 1
- Johns Hopkins, Baltimore
A Study of First-Line Olomorasib (LY3537982) and Pembrolizumab With or Without Chemotherapy in Patients With Advanced KRAS G12C-Mutant Non-small Cell Lung Cancer
Набиране на участнициФаза 3
- Johns Hopkins Bayview Medical Center, Baltimore
A Study Evaluating the Efficacy and Safety of Divarasib and Pembrolizumab Versus Pembrolizumab and Pemetrexed and Carboplatin or Cisplatin in Participants With Previously Untreated, KRAS G12C-Mutated, Advanced or Metastatic Non-Squamous Non-Small Cell Lung Cancer
Набиране на участнициФаза 3
- Saint Agnes Hospital - Baltimore - Hunt - PPDS, Baltimore
Open-label Study of BBO-8520 in Adult Subjects With KRASG12C Non-small Cell Lung Cancer
Набиране на участнициФаза 1
- University of Maryland Marlene & Stewart Greenebaum Comprehensive Cancer Center, Baltimore
A Study of Pembrolizumab With or Without Chemotherapy in Combination With Additional Treatments for Advanced Non-Small Cell Lung Cancer (NSCLC) (MK-3475-01G/KEYMAKER U01)
Набиране на участнициФаза 2
- MedStar Franklin Square Medical Center ( Site 0033), Baltimore
Testing the Addition of High Dose, Targeted Radiation to the Usual Treatment for Locally-Advanced Inoperable Non-Small Cell Lung Cancer
Набиране на участнициФаза 3
- Greater Baltimore Medical Center, Baltimore
- Sinai Hospital of Baltimore, Baltimore
Testing Proton Craniospinal Radiation Therapy Versus the Usual Radiation Therapy for Leptomeningeal Metastasis, RADIATE-LM Trial
Набиране на участнициФаза 3
- Johns Hopkins University/Sidney Kimmel Cancer Center, Baltimore
Immunobiology Blood and Tissue Collection of Upper Aerodigestive Malignancies
Набиране на участнициНаблюдателно проучване
- Johns Hopkins University, Baltimore
Signature Development and Validation Protocol for an Epigenetic Assay in Diagnosing Lung Cancer
Набиране на участнициНаблюдателно проучванеЗдравите доброволци са добре дошли
- University of Maryland Baltimore Washington Medical Center, Glen Burnie · на 9 мили
A Study of Peluntamig (PT217) in Patients With Neuroendocrine Carcinomas Expressing DLL3 (the SKYBRIDGE Study)
Набиране на участнициФаза 1/2
- Sidney Kimmel Comprehensive Cancer Center at John Hopkins, Baltimore
EXoPERT EMERALD Clinical Study
Набиране на участнициНаблюдателно проучванеЗдравите доброволци са добре дошли
- John Hopkins University, Baltimore
GCC 2546- Motion Management
Набиране на участници
- University of Maryland Greenebaum Cancer Center, Baltimore
Comparing Combinations of Targeted Drugs for Advanced Non-Small Cell Lung Cancer That Has EGFR and MET Gene Changes (A Lung-MAP Treatment Trial)
Набиране на участнициФаза 2
- Kaiser Permanente-Woodlawn Medical Center, Baltimore
- Kaiser Permanente Lutherville - Timonium Medical Center, Lutherville · на 9 мили
Study of RMC-9805 in Participants With KRAS G12D-Mutant Solid Tumors
Набиране на участнициФаза 1
- Johns Hopkins University, Baltimore
A Study to Evaluate the Safety, Tolerability, and Efficacy of BMS-986523 Alone and in Combination With Anti-Cancer Agents in Participants With Advanced Solid Malignancies
Набиране на участнициФаза 1/2
- Johns Hopkins Hospital, Baltimore
Study of RMC-6236 in Patients With Advanced Solid Tumors Harboring Specific Mutations in RAS
Набиране на участнициФаза 1/2
- Johns Hopkins University, Baltimore
Adding the Immunotherapy Drug Cemiplimab to Usual Treatment for People With Advanced Non-Small Cell Lung Cancer Who Had Previous Treatment With Platinum Chemotherapy and Immunotherapy (An Expanded Lung-MAP Treatment Trial)
Набиране на участнициФаза 2/3
- Saint Agnes Hospital, Baltimore
- Kaiser Permanente-Woodlawn Medical Center, Baltimore
- Kaiser Permanente Lutherville - Timonium Medical Center, Lutherville · на 9 мили
Targeted Treatment for Advanced Non-Small Cell Lung Cancer That Has a MET Exon 14 Skipping Gene Change (An Expanded Lung-MAP Treatment Trial)
Набиране на участнициФаза 2
- Kaiser Permanente-Woodlawn Medical Center, Baltimore
- Kaiser Permanente Lutherville - Timonium Medical Center, Lutherville · на 9 мили
Study to Evaluate Sutetinib Maleate Capsule in Locally Advanced or Metastatic Non-small Cell Lung Cancer
Набиране на участнициФаза 2
- University of Maryland Medical Center, Baltimore
A Phase 1/2 Study of VS-7375 in Patients With KRAS G12D-Mutated Solid Tumors
Набиране на участнициФаза 1/2
- Johns Hopkins University, Baltimore
Durvalumab and Tremelimumab in Combination With Chemotherapy in HIV-infected Patients With Non-small Cell Lung Cancer
Набиране на участнициФаза 2
- Marlene and Stewart Greenebaum Comprehensive Cancer Center, Baltimore
- Harry and Jeannette Weinberg Cancer Institute at Franklin Square, Baltimore
Veterans Affairs Lung Cancer Surgery Or Stereotactic Radiotherapy
Набиране на участници
- Baltimore VA Medical Center VA Maryland Health Care System, Baltimore, MD, Baltimore
A Study of CLSP-1025 in Adult Patients With Solid Tumors That Harbor the p53 R175H Mutation
Набиране на участнициФаза 1
- Johns Hopkins - Sidney Kimmel Comprehensive Cancer Center, Baltimore
Study of PLK1 Inhibitor, Onvansertib, in Relapsed Small Cell Lung Cancer
Набиране на участнициФаза 2
- University of Maryland Greenebaum Comprehensive Cancer Center, Baltimore
Full-Field Optical Coherence Tomography (FFOCT) for Evaluation of Bronchoscopic Small Biopsy Specimens
Набиране на участнициНаблюдателно проучване
- Johns Hopkins Hospital, Baltimore
SYNERGY-AI: Artificial Intelligence Based Precision Oncology Clinical Trial Matching and Registry
Набиране на участнициНаблюдателно проучване
- Massive Bio SYNERGY-AI site, Baltimore
- Massive Bio SYNERGY-AI site, Towson · на 8 мили
Clinical Validation of Freenome Multiomics Blood Test for Lung Cancer Screening
Набиране на участнициНаблюдателно проучване
- Ascension St. Agnes Hospital, Baltimore
Clinical Utility of Management of Patients With Pulmonary Nodules Using the Percepta Nasal Swab Classifier
Набиране на участнициНаблюдателно проучване
- University of Maryland Medical Center, Baltimore
First in Human Phase 1 Study of AG01 Anti-Progranulin/GP88 Antibody in Advanced Solid Tumor Malignancies
Набиране на участнициФаза 1
- University of Maryland Greenebaum Comprehensive Cancer Center, Baltimore
Проучвания за Рак на белия дроб в други градове
- Houston, TX78 проучвания
- Boston, MA62 проучвания
- New York City, NY60 проучвания
- Los Angeles, CA45 проучвания
- Arlington, VA41 проучвания
- Washington, DC41 проучвания
- Chicago, IL41 проучвания
- Nashville, TN40 проучвания
- St. Louis, MO39 проучвания
- Columbus, OH37 проучвания
- Philadelphia, PA36 проучвания
- Seattle, WA33 проучвания
Други проучвания в Baltimore
- Рак на белия дроб с недребноклетъчен тип60 проучвания
- Рак на гърдата47 проучвания
- Рак на простатата43 проучвания
- Рак (всички видове)37 проучвания
- Рак на панкреаса31 проучвания
- Колоректален рак31 проучвания
- Метастатичен рак28 проучвания
- Затлъстяване26 проучвания
- Рак на пикочния мехур24 проучвания
- Сърдечна недостатъчност24 проучвания
- Рак на яйчниците22 проучвания
- Инсульт21 проучвания
От ClinicalTrials.gov, данни към 6.10.2026 г.. Всяко проучване има свои критерии за участие; екипът на проучването определя кой може да се включи.